Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial.
Hirsch A, Nijveldt R, van der Vleuten PA, Tio RA, van der Giessen WJ, Marques KM, Doevendans PA, Waltenberger J, Ten Berg JM, Aengevaeren WR, Biemond BJ, Tijssen JG, van Rossum AC, Piek JJ, Zijlstra F. Hirsch A, et al. Among authors: waltenberger j. Catheter Cardiovasc Interv. 2008 Feb 15;71(3):273-81. doi: 10.1002/ccd.21337. Catheter Cardiovasc Interv. 2008. PMID: 18288734 Clinical Trial.
Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results.
van der Laan A, Hirsch A, Nijveldt R, van der Vleuten PA, van der Giessen WJ, Doevendans PA, Waltenberger J, Ten Berg JM, Aengevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ. van der Laan A, et al. Among authors: waltenberger j. Neth Heart J. 2008 Dec;16(12):436-9. doi: 10.1007/BF03086194. Neth Heart J. 2008. PMID: 19127324 Free PMC article.
Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial.
Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA, Waltenberger J, ten Berg JM, Doevendans PA, Aengevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Piek JJ, Zijlstra F; HEBE Investigators. Hirsch A, et al. Among authors: waltenberger j. Eur Heart J. 2011 Jul;32(14):1736-47. doi: 10.1093/eurheartj/ehq449. Epub 2010 Dec 10. Eur Heart J. 2011. PMID: 21148540 Clinical Trial.
Long term outcome after mononuclear bone marrow or peripheral blood cells infusion after myocardial infarction.
Delewi R, van der Laan AM, Robbers LF, Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, Tio RA, Waltenberger J, Ten Berg JM, Doevendans PA, Gehlmann HR, van Rossum AC, Piek JJ, Zijlstra F; HEBE investigators. Delewi R, et al. Among authors: waltenberger j. Heart. 2015 Mar;101(5):363-8. doi: 10.1136/heartjnl-2014-305892. Epub 2014 Oct 7. Heart. 2015. PMID: 25294647 Clinical Trial.
Genetic inflammatory factors predict restenosis after percutaneous coronary interventions.
Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, Quax PH, van Vlijmen BJ, Atsma DE, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: waltenberger j. Circulation. 2005 Oct 18;112(16):2417-25. doi: 10.1161/CIRCULATIONAHA.105.536268. Circulation. 2005. PMID: 16230497
Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1.
Wijpkema JS, van Haelst PL, Monraats PS, Bruinenberg M, Zwinderman AH, Zijlstra F, van der Steege G, de Winter RJ, Doevendans PA, Waltenberger J, Jukema JW, Tio RA. Wijpkema JS, et al. Among authors: waltenberger j. Pharmacogenet Genomics. 2006 May;16(5):331-7. doi: 10.1097/01.fpc.0000205001.07054.fa. Pharmacogenet Genomics. 2006. PMID: 16609364
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions.
Pons D, Monraats PS, de Maat MP, Pires NM, Quax PH, van Vlijmen BJ, Rosendaal FR, Zwinderman AH, Doevendans PA, Waltenberger J, de Winter RJ, Tio RA, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Pons D, et al. Among authors: waltenberger j. Thromb Haemost. 2007 Dec;98(6):1323-8. Thromb Haemost. 2007. PMID: 18064331
Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention.
Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Huizinga TW, Eefting D, Quax PH, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: waltenberger j. Genes Immun. 2007 Jan;8(1):44-50. doi: 10.1038/sj.gene.6364343. Epub 2006 Nov 23. Genes Immun. 2007. PMID: 17122782
304 results